These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1715220)

  • 1. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
    Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).
    Edelberg JM; Reilly CF; Pizzo SV
    J Biol Chem; 1991 Apr; 266(12):7488-93. PubMed ID: 1708387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
    Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
    J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
    Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
    J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
    Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
    Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
    Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
    J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
    Walker B; Elmore DT
    Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
    Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
    J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
    Coleman PL; Patel PD; Cwikel BJ; Rafferty UM; Sznycer-Laszuk R; Gelehrter TD
    J Biol Chem; 1986 Mar; 261(9):4352-7. PubMed ID: 2936742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of proteases type plasminogen activator and their inhibitor in cornea.
    Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
    Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
    Lawrence D; Strandberg L; Grundström T; Ny T
    Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.
    York JD; Li P; Gardell SJ
    J Biol Chem; 1991 May; 266(13):8495-500. PubMed ID: 2022663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
    Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
    Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator.
    Stoop A; van Meijer M; Horrevoets AJ; Pannekoek H
    Trends Cardiovasc Med; 1997 Feb; 7(2):47-51. PubMed ID: 21235863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.